Loading clinical trials...
Loading clinical trials...
The metabolism of PF-00868554 is primarily mediated by CYP3A, and it is anticipated that hepatic impairment will modify PF-00868554 plasma concentrations. Hence, it is important to determine the impac...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT06953479 · HEPATITIS C (HCV), Incarceration, and more
NCT05968573 · Human Immunodeficiency Virus (HIV), Hepatitis C (HCV)
NCT05657106 · Opioid-Related Disorders, Hepatitis C (HCV), and more
NCT07317687 · HIV Testing, HEPATITIS C (HCV), and more
NCT06799702 · HIV Pre-exposure Prophylaxis, HEPATITIS C (HCV), and more
Pfizer Investigational Site
Anaheim, California
Pfizer Investigational Site
Anaheim, California
Pfizer Investigational Site
Miami, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions